Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of Radicava™ (Edaravone) to Treat ALS
Retrieved on:
Thursday, October 4, 2018
In March of 2018, MTPA established the subsidiary MTP-CA to facilitate the distribution of RADICAVA in Canada.
Key Points:
- In March of 2018, MTPA established the subsidiary MTP-CA to facilitate the distribution of RADICAVA in Canada.
- Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) through an iterative clinical development platform over a 13-year period.
- About Mitsubishi Tanabe Pharma Canada, Inc.
Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS. - About Mitsubishi Tanabe Pharma America, Inc.
Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America.